RLMD

Relmada Therapeutics, Inc.

Price Chart

Latest Quote

$6.73

+0.13 (+1.97%)

Current Price

Previous Close	$6.60
Open	$6.81
Day High	$6.84
Day Low	$6.48
Volume	4,106,676

Fetched: 2026-06-21T08:15:51

Stock Information

Shares Outstanding	104.99M
Total Debt	$110K
Cash Equivalents	$116.44M
Net Income	$-15.01M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$706.56M
EPS (TTM)	$-1.09
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$-39.65M
Income	$-15.01M
Book/sh	$1.18
Cash/sh	$1.11
Employees	17

Financial Ratios

Quick Ratio	79.92
Current Ratio	80.21
Debt/Eq	0.10

Returns & Margins

ROA	-14.38%
ROE	-25.62%

Ownership

Insider Ownership	2.90%
Institutional Ownership	88.63%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-16.41
P/B	5.70

Analyst Data

Recommendation	strong_buy
Target Price	$12.67

Technical Indicators

SMA20	$6.64
SMA50	$7.03
SMA200	$4.61
RSI	42.16
ATR	0.4330

Shares Float	7.72M
Short Float	5.92%
Short Ratio	6.27
Rel Volume	3.05

Performance History

Week	+3.22%
Month	-4.27%
Quarter	+7.68%
6 Months	+49.56%
YTD	+54.00%
Year	+855.97%
3 Years	+148.34%
5 Years	-78.39%
10 Years	-41.98%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$6.73	4,106,700
2026-06-17	$6.60	1,358,700
2026-06-16	$6.55	2,024,200
2026-06-15	$6.37	3,076,200
2026-06-12	$6.65	1,127,900
2026-06-11	$6.52	865,400
2026-06-10	$6.38	1,456,400
2026-06-09	$6.27	1,685,200
2026-06-08	$5.72	1,575,400
2026-06-05	$5.95	1,255,400
2026-06-04	$6.31	817,100
2026-06-03	$6.33	798,700
2026-06-02	$6.42	1,909,700
2026-06-01	$6.85	711,000
2026-05-29	$7.21	946,300
2026-05-28	$7.25	501,300
2026-05-27	$7.26	556,000
2026-05-26	$7.17	726,400
2026-05-22	$7.04	668,700
2026-05-21	$7.21	723,000
2026-05-20	$7.17	763,900
2026-05-19	$7.03	1,459,200

About Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

📰 Latest News

Relmada Therapeutics (RLMD): 10 Best Growth Stocks Under $30 to Buy Now

Insider Monkey • 2026-06-19T07:01:16Z

Relmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights: Strong Financial Position and ...

GuruFocus.com • 2026-05-13T05:02:01Z

Relmada Therapeutics Q1 Earnings Call Highlights

MarketBeat • 2026-05-13T02:06:18Z

Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?

Zacks • 2026-04-13T13:55:02Z

Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics

Zacks • 2026-04-06T15:10:00Z

5 Small Drug Stocks to Buy as Sector Recovery Gains Strength

Zacks • 2026-04-02T14:00:00Z

Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know

Zacks • 2026-03-26T13:55:01Z

Here’s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock

Insider Monkey • 2026-03-25T05:34:10Z

Relmada Therapeutics Inc (RLMD) Q4 2025 Earnings Call Highlights: Strategic Advancements and ...

GuruFocus.com • 2026-03-20T03:01:25Z

Relmada Therapeutics, Inc. Q4 2025 Earnings Call Summary

Moby • 2026-03-20T00:14:56Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$59,100,200	$83,891,036	$103,702,293	$161,249,076
Other Income Expense	$319,048	$381,661	$-241,157	$1,545,829
Net Non Operating Interest Income Expense	$1,395,989	$3,530,021	$5,151,704	$2,659,424
Operating Expense	$59,100,200	$83,891,036	$103,702,293	$161,249,076
General And Administrative Expense	$32,221,054	$37,715,524	$48,894,945	$47,926,077
Other Non Operating Income Expenses	-	-	-	$6,351,606
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-57,385,163	$-79,979,354	$-98,791,746	$-157,043,823
Net Interest Income	$1,395,989	$3,530,021	$5,151,704	$2,659,424
Interest Income	$1,395,989	$3,530,021	$5,151,704	$2,659,424
Normalized Income	$-57,704,211	$-80,361,015	$-98,550,589	$-152,238,046
Net Income From Continuing And Discontinued Operation	$-57,385,163	$-79,979,354	$-98,791,746	$-157,043,823
Total Operating Income As Reported	$-59,100,200	$-83,891,036	$-103,702,293	$-161,249,076
Net Income Common Stockholders	$-57,385,163	$-79,979,354	$-98,791,746	$-157,043,823
Net Income	$-57,385,163	$-79,979,354	$-98,791,746	$-157,043,823
Net Income Including Noncontrolling Interests	$-57,385,163	$-79,979,354	$-98,791,746	$-157,043,823
Net Income Continuous Operations	$-57,385,163	$-79,979,354	$-98,791,746	$-157,043,823
Pretax Income	$-57,385,163	$-79,979,354	$-98,791,746	$-157,043,823
Interest Income Non Operating	$1,395,989	$3,530,021	$5,151,704	$2,659,424
Operating Income	$-59,100,200	$-83,891,036	$-103,702,293	$-161,249,076
Per Share
Diluted EPS	$-1.45	$-2.65	$-3.28	$-5.30
Basic EPS	$-1.45	$-2.65	$-3.28	$-5.30
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-59,419,248	$-84,272,697	$-103,461,136	$-156,443,299
Total Unusual Items	$319,048	$381,661	$-241,157	$-4,805,777
Total Unusual Items Excluding Goodwill	$319,048	$381,661	$-241,157	$-4,805,777
EBITDA (Bullshit earnings)	$-59,100,200	$-83,891,036	$-103,702,293	$-161,249,076
EBIT	$-59,100,200	$-83,891,036	$-103,702,293	$-161,249,076
Diluted Average Shares	$39,479,694	$30,163,751	$30,099,203	$29,628,664
Basic Average Shares	$39,479,694	$30,163,751	$30,099,203	$29,628,664
Diluted NI Availto Com Stockholders	$-57,385,163	$-79,979,354	$-98,791,746	$-157,043,823
Gain On Sale Of Security	$319,048	$381,661	$-241,157	$-4,805,777
Research And Development	$26,879,146	$46,175,512	$54,807,348	$113,322,999
Selling General And Administration	$32,221,054	$37,715,524	$48,894,945	$47,926,077
Other Gand A	$32,221,054	$37,715,524	$48,894,945	$47,926,077
Reconciled Depreciation	-	-	-	$0

Fetched: 2026-06-17

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$86,512,013	$35,521,961	$85,357,242	$140,436,302
Total Assets	$94,003,471	$45,817,818	$97,552,042	$152,905,179
Total Non Current Assets	$19,500	$21,975	$43,125	$34,875
Other Non Current Assets	$19,500	$21,975	$43,125	$34,875
Current Assets	$93,983,971	$45,795,843	$97,508,917	$152,870,304
Prepaid Assets	$977,721	$886,461	$1,185,057	$4,035,186
Cash Cash Equivalents And Short Term Investments	$93,006,250	$44,909,382	$96,323,860	$148,322,686
Cash And Cash Equivalents	$3,496,540	$3,857,026	$4,091,568	$5,395,905
Receivables	-	-	$0	$512,432
Other Current Assets	-	-	-	$-14
Other Receivables	-	-	-	$512,432
Cash Financial	-	-	-	$5,395,905
Liabilities
Total Liabilities Net Minority Interest	$7,491,458	$10,295,857	$12,194,800	$12,468,877
Total Non Current Liabilities Net Minority Interest	$1,060,931	$4,467	$0	$0
Current Liabilities	$6,430,527	$10,291,390	$12,194,800	$12,468,877
Other Current Liabilities	$-17	$27	$-9	$41
Payables And Accrued Expenses	$5,895,044	$9,137,363	$9,190,209	$11,446,936
Payables	$1,568,944	$4,130,563	$3,506,009	$5,261,936
Accounts Payable	$1,568,944	$4,130,563	$3,506,009	$5,261,936
Equity
Common Stock Equity	$86,512,013	$35,521,961	$85,357,242	$140,436,302
Total Equity Gross Minority Interest	$86,512,013	$35,521,961	$85,357,242	$140,436,302
Stockholders Equity	$86,512,013	$35,521,961	$85,357,242	$140,436,302
Retained Earnings	$-698,267,198	$-640,882,035	$-560,902,681	$-462,110,935
Other
Ordinary Shares Number	$73,333,622	$30,174,202	$30,099,203	$30,099,203
Share Issued	$73,333,622	$30,174,202	$30,099,203	$30,099,203
Tangible Book Value	$86,512,013	$35,521,961	$85,357,242	$140,436,302
Invested Capital	$86,512,013	$35,521,961	$85,357,242	$140,436,302
Working Capital	$87,553,444	$35,504,453	$85,314,117	$140,401,427
Total Capitalization	$86,512,013	$35,521,961	$85,357,242	$140,436,302
Additional Paid In Capital	$784,705,878	$676,373,822	$646,229,824	$602,517,138
Capital Stock	$73,333	$30,174	$30,099	$30,099
Common Stock	$73,333	$30,174	$30,099	$30,099
Preferred Stock	$0	$0	$0	$0
Employee Benefits	$1,060,931	$4,467	$0	-
Pensionand Other Post Retirement Benefit Plans Current	$535,500	$1,154,000	$3,004,600	$1,021,900
Current Accrued Expenses	$4,326,100	$5,006,800	$5,684,200	$6,185,000
Other Short Term Investments	$89,509,710	$41,052,356	$92,232,292	$142,926,781
Treasury Shares Number	-	-	$0	-
Net PPE	-	-	-	-
Accumulated Depreciation	-	-	-	-
Gross PPE	-	-	-	-
Machinery Furniture Equipment	-	-	-	-

Fetched: 2026-06-17

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-45,786,988	$-51,755,798	$-51,659,206	$-103,801,617
Operating Activities
Operating Cash Flow	$-45,786,988	$-51,755,798	$-51,659,206	$-103,801,617
Cash Flow From Continuing Operating Activities	$-45,786,988	$-51,755,798	$-51,659,206	$-103,801,617
Operating Gains Losses	$79,207	$-374,926	$4,064,391	$585,522
Investing Activities
Investing Cash Flow	$-48,138,306	$51,561,597	$50,453,332	$19,733,609
Cash Flow From Continuing Investing Activities	$-48,138,306	$51,561,597	$50,453,332	$19,733,609
Financing Activities
Issuance Of Capital Stock	$93,637,829	$0	$0	$42,728,599
Financing Cash Flow	$93,564,808	$-40,341	$-98,463	$45,020,474
Cash Flow From Continuing Financing Activities	$93,564,808	$-40,341	$-98,463	$45,020,474
Net Other Financing Charges	$-73,021	$-287,088	$-98,463	$323,632
Net Common Stock Issuance	$93,637,829	$0	$0	$42,728,599
Common Stock Issuance	$93,637,829	$0	$0	$42,728,599
Other
End Cash Position	$3,496,540	$3,857,026	$4,091,568	$5,395,905
Beginning Cash Position	$3,857,026	$4,091,568	$5,395,905	$44,443,439
Changes In Cash	$-360,486	$-234,542	$-1,304,337	$-39,047,534
Proceeds From Stock Option Exercised	$0	$246,747	$0	$1,968,243
Net Investment Purchase And Sale	$-48,138,306	$51,561,597	$50,453,332	$19,733,609
Sale Of Investment	$35,690,270	$63,641,225	$140,916,864	$67,027,372
Purchase Of Investment	$-83,828,576	$-12,079,628	$-90,463,532	$-47,293,763
Change In Working Capital	$-3,949,648	$-1,583,664	$3,080,234	$10,593,270
Change In Payables And Accrued Expense	$-3,860,863	$-1,903,410	$-274,077	$3,759,558
Change In Accrued Expense	$-1,299,244	$-2,527,964	$1,481,850	$3,338,518
Change In Payable	$-2,561,619	$624,554	$-1,755,927	$421,040
Change In Account Payable	$-2,561,619	$624,554	$-1,755,927	$421,040
Change In Prepaid Assets	$-88,785	$319,746	$2,841,879	$7,259,767
Other Non Cash Items	$905,226	-	-	$-6,351,606
Stock Based Compensation	$14,961,645	$30,188,881	$43,811,149	$44,194,765
Unrealized Gain Loss On Investment Securities	$-398,255	$-6,735	$-3,823,234	$4,220,255
Gain Loss On Investment Securities	$79,207	$-374,926	$4,064,391	$585,522
Net Income From Continuing Operations	$-57,385,163	$-79,979,354	$-98,791,746	$-157,043,823
Change In Receivables	-	$0	$512,432	$-426,055
Depreciation Amortization Depletion	-	-	-	$0
Depreciation And Amortization	-	-	-	$0
Depreciation	-	-	-	$0
Repayment Of Debt	-	-	-	-
Interest Paid Supplemental Data	-	-	-	-
Net Issuance Payments Of Debt	-	-	-	-
Net Long Term Debt Issuance	-	-	-	-
Long Term Debt Payments	-	-	-	-

Fetched: 2026-06-17